The above loss- and gain-of EZH2 function in vivo bone metastasis experiments demonstrated that EZH2 promoted breast cancer bone metastasis and that EZH2’s effect on bone metastasis is likely methyltransferase-independent. The gene discussed is EZH2; the disease is breast cancer.